SCHEMBL18436793

SCHEMBL18436793

CCCOC(=O)N1[C@H](C)CN(c2ccc(C)cc2)C[C@@H]1C

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40
POLB P06746 2/20 0.40
MAPT P10636 3/20 0.39
LMNA P02545 2/20 0.39
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
RAB9A P51151 2/20 0.39
GPR119 Q8TDV5 1/20 0.37
ALDH1A1 P00352 4/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HTR2C P28335 1/20 0.36
ACACB O00763 2/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19012590 1.00 SMN1; SMN2 (0.40) SMN1; SMN2TP53HPGDPOLBMAPT
SCHEMBL18436372 0.92 MAPT (0.46) SMN1; SMN2MAPTLMNAGAAKDM4E
SCHEMBL19012591 0.92 MAPT (0.46) SMN1; SMN2MAPTLMNAGAAKDM4E
SCHEMBL21336663 0.88 POLB (0.36) SMN1; SMN2TP53HPGDPOLBMAPT
SCHEMBL19012522 0.88 SMN1; SMN2 (0.40) SMN1; SMN2TP53HPGDMAPTLMNA
SCHEMBL19012393 0.86 ACACB (0.43) SMN1; SMN2TP53HPGDGAAKDM4E
SCHEMBL19001043 0.86 ACACB (0.40) SMN1; SMN2TP53HPGDMAPTLMNA
SCHEMBL19001140 0.86 ACACB (0.40) SMN1; SMN2TP53HPGDMAPTLMNA
SCHEMBL19012516 0.81 L3MBTL1 (0.41) SMN1; SMN2MAPTLMNAKDM4ERAB9A
SCHEMBL18436107 0.81 L3MBTL1 (0.41) SMN1; SMN2MAPTLMNAKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124482-B1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) 2019-09-11 EP disclosed
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-06-22 US disclosed
EP-3124482-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS SMO, GLI1, SHH SMN1; SMN2 4029/4885TP53 683/4885HPGD 1225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.